Showing archive for: “Pharmaceutical Industry”
Law and Economics 2.0
Readers of TOTM know that the future of law and economics is a frequent topic of discussion here, and a topic in which I am both personally invested and spend a good deal of time thinking about (see, e.g. my blog series on the future of law and economics here). Legal Pad (at CNN/Fortune Magazine) ... Law and Economics 2.0
Global Competition Policy Symposium on Section 5
The newest issue in Global Competition Policy includes a symposium (disclosure: for which I was the senior editor) on Section 5 enforcement under the FTC Act. Contributors included Commissioner Rosch’s attorney advisor Kyle Andeer, Doug Melamed (WilmerHale) and Joe Sims. My views on the expansion of Section 5 in the standard setting context, at least ... Global Competition Policy Symposium on Section 5
Antitrust under President Obama: "I will direct my administration to reinvigorate antitrust enforcement"
Danny Sokol makes some predictions about Post-Obama antitrust, and about my disappointment in what he perceives to be the likely direction of antitrust policy in the Obama administration: 1. increased challenges of mergers and monopolization cases, especially at DOJ 2. more consumer protection work at the FTC with a push to more expansive consumer rights ... Antitrust under President Obama: "I will direct my administration to reinvigorate antitrust enforcement"
Odd FTC Consent in Vertical Licensing Case
The FTC announced a complaint today challenging Fresenius Medical Care AG & Co.’s proposed acquisition of an exclusive sublicense from Luitpold Pharmaceuticals, who is in turn a wholly owned subsidiary of a Japanese firm Daiichi Sankyo Company. The sublicense would allow Fresenius to manufacturer and supply the intravenous iron drug Venofer to dialysis clinics in ... Odd FTC Consent in Vertical Licensing Case
Organ Markets, Social Justice, and the Poor: A Reply to Professor Pasquale
Frank Pasquale at Madisonian is concerned that organ markets do not show enough concern for the poor. He writes: I’d be more sympathetic to the economic approach to the topic if it showed a bit more concern for the plight of those unable to pay for organs (and for the very poor in LDC’s whose ... Organ Markets, Social Justice, and the Poor: A Reply to Professor Pasquale
The FTC Takes On the DOJ in Schering-Plough
There is a very interesting development in the ongoing saga of the FTC v. Schering-Plough Corporation, a very important antitrust case involving a payment from a branded pharmaceutical manufacturer to a generic to delay entry (a “reverse payment”). The interesting development is that the FTC, who offered a brief in favor of cert., has now ... The FTC Takes On the DOJ in Schering-Plough
